Home » Blog » Company News

Company News

  • Understanding MC903 Induced AD Model in Detail

    2024-08-21

    Understanding MC903 Induced AD Model in DetailAtopic dermatitis (AD) is a chronic inflammatory skin condition characterized by erythematous plaques, eruptions, elevated serum IgE levels, and a T helper cell type 2 (Th2) cytokine profile, including interleukin-4 (IL-4) and interleukin-13 (IL-13). Mic Read More
  • What is an SLE Model?

    2024-08-19

    Systemic Lupus Erythematosus (SLE) is a complex autoimmune disease that affects multiple organ systems in the body. It is characterized by the production of autoantibodies and the formation of immune complexes, which subsequently lead to inflammation and damage to various tissues. The symptoms of SL Read More
  • What is the Function of AD Model?

    2024-08-17

    IntroductionAtopic Dermatitis (AD) is a chronic inflammatory skin condition characterized by erythematous plaques, eruptions, and elevated serum IgE levels. It affects millions of people worldwide, causing significant discomfort and impacting the quality of life. The development of effective treatme Read More
  • How Are Animal Models Revolutionizing SLE Model Research?

    2024-08-15

    Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that can affect virtually any organ system, leading to a wide range of symptoms and complications. Understanding this complex disease is a challenge that many researchers have faced over the years. The introduction of animal models i Read More
  • Company Headquarters Relocates to Suzhou Ascendas iHub Park

    2024-04-09

    Suzhou, China – April 8, 2023 –HKeybio, a leading industry player in Autoimmune disease models, is excited to announce the relocation of its headquarters to 2nd floor, Building B, Ascendas iHub Suzhou. The move comes as a result of the company's rapid expansion and growth.The new office space is des Read More
  • Celebrate Chinese New Year by Making Dumplings

    2024-04-09

    On February 8, 2024, colleagues at HKeybio Company came together to celebrate the Chinese New Year by making traditional dumplings. The festive atmosphere was filled with joy, laughter, and the delicious aroma of dumplings cooking in the kitchen.Employees from different departments gathered in the c Read More
  • HKeybio to Participate in BIO CHINA 2024

    2024-04-09

    Suzhou, China - HKeybio, a leading biotechnology company specializing in auotimmune disease models, is excited to announce its participation in the upcoming BIO China Conference scheduled to take place from March 14 to 16, 2024. The conference will be held at the Suzhou International Expo Center, wi Read More
  • BIO EUROPE 2023| Help HKeybio Enter the International Market

    2024-04-09

    BIO-Europe 2023 was grandly opened on November 6-8, 2023 in Munich, Germany. BIO-Europe has long been a hub for innovation in the biotech, pharmaceutical, and financial sectors. The event is held annually in a different city, building a strong network of medical professionals from more than 60 count Read More
  • HKeybio to Partcipate in 2024 BIO

    2024-04-09

    San Diego, California, 2024 – HKeybio, a leading biotechnology company specializing in autoimmune diseases, announces its participation at the upcoming 2024 BIO and Exhibition in the United States.The 2024 BIO, one of the most prestigious events in the biotechnology industry, will be held from June Read More
  • Total 2 pages  Go to Page
  • Go
HKeybio is a Contract Research Organization (CRO) specializing in preclinical research within the field of autoimmune diseases.

Quick Links

Service Catagory

Contact Us

  Phone
Business Manager-Julie Lu:+86-18662276408
Business Inquiry-Will Yang:+86-17519413072
Technical Consultation-Evan Liu:+86-17826859169
  info@hkeybio.com; tech@hkeybio.com
  Add: Building B, No.388 Xingping Street, Ascendas iHub Suzhou Industrial Park, JIANGSU, CHINA
Leave a Message
Contact Us
Sign up for our newsletter to receive the latest news.
​Copyright © 2024 HkeyBio. All rights reserved. | Sitemap | Privacy Policy